UroGen Pharma Ltd. Annual Income Tax Expense (Benefit) in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
UroGen Pharma Ltd. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2017 to 2023.
  • UroGen Pharma Ltd. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $91K.
  • UroGen Pharma Ltd. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $4.04M, a 435% increase year-over-year.
  • UroGen Pharma Ltd. annual Income Tax Expense (Benefit) for 2023 was $3.92M, a 123% increase from 2022.
  • UroGen Pharma Ltd. annual Income Tax Expense (Benefit) for 2022 was $1.76M, a 21.1% increase from 2021.
  • UroGen Pharma Ltd. annual Income Tax Expense (Benefit) for 2021 was $1.45M, a 57.1% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $3.92M +$2.17M +123% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-14
2022 $1.76M +$306K +21.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 $1.45M -$1.93M -57.1% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-24
2020 $3.37M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-21
2018 $125K +$106K +558% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-02
2017 $19K Jan 1, 2017 Dec 31, 2017 10-K 2020-03-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.